Anissa Cherkaoui’s Post

🌍 Join Us in Transforming Healthcare Access in Africa 🌍 At MedNord AB, we’re driven by a powerful vision: making high-quality, affordable healthcare accessible across Africa. With our robust distribution network and established partnerships in the region, we’re ready to help pharmaceutical companies reach new, high-demand markets. Why Partner with MedNord AB? Extensive Market Reach: Our deep local insights and established partnerships enable smooth, scalable entry into diverse African regions. Rapid Growth Potential: The demand for essential medications, chronic disease treatments, and innovative therapies is rising across the continent. Proven Expertise: From navigating regulatory requirements to providing efficient distribution, we have the know-how to support successful market expansion. We’re seeking pharmaceutical companies and healthcare innovators eager to make a difference and expand their global reach. If your company is ready to seize the opportunity of tapping into Africa’s growing healthcare market, let’s collaborate. 🤝 Ready to take the next step? Partner with MedNord AB to expand your reach and bring transformative healthcare solutions to the African market. Let’s explore how we can make a powerful impact together. #HealthcareInnovation #PharmaceuticalPartnership #GlobalExpansion #MedNordAB

Argentina, Brazil, and Colombia are emerging as key players in clinical trials across South America. But what makes these nations so attractive to pharmaceutical companies and clinical research organizations? 1. Diverse Population These countries boast a wide variety of genetic backgrounds, health conditions, and lifestyles, which are essential for conducting representative clinical trials. This diversity ensures that results can be applied to different population groups, making them more globally relevant.   2.   Health Infrastructure Argentina, Brazil, and Colombia have developed robust public and private health infrastructures. Many medical centers and hospitals are equipped with advanced technology and staffed by highly trained professionals, enabling efficient and safe implementation of clinical trials.    3.  Favorable Regulations The regulatory frameworks in these countries have evolved to streamline the process of conducting clinical trials. Health authorities are supportive of innovation and research, leading to more efficient approval processes for researchers.    4.  Competitive Costs Clinical trials in Latin America tend to be more cost-effective compared to other regions, allowing pharmaceutical companies to optimize resources without compromising the quality of research.    5.  Commitment to Research These countries have shown a growing commitment to research and development of new therapies. Strong partnerships between academic institutions, hospitals, and pharmaceutical companies foster collaboration, driving innovation and enhancing the quality of clinical trials.   With their diversity, solid infrastructure, favorable regulations, competitive costs, and dedication to research, Argentina, Brazil, and Colombia are becoming strategic points for pharmaceutical companies focused on advancing innovative treatments. #BRCRGlobal #ClinicalTrials #Research #Argentina #Brazil #Colombia #GlobalHealth #Pharma #Pharmaceuticals 

🌟 Welcome to Episode 9 of our KYM Series! 🌟 In this edition, we take a closer look at Singapore’s evolving pharmaceutical market, uncovering critical insights that are vital for industry leaders to stay informed. Here’s what we cover: 🔍 Market Size – Current trends and growth opportunities. 💊 Branded vs. Generic Drugs – The evolving landscape of distribution. 🏭 Local Manufacturing vs. Imports – A closer look at domestic production versus global supply chain dependence. 🩺 Major Therapy Areas – Spotlighting key therapeutic fields such as diabetes, oncology, cardiovascular diseases, and more. 🏥 Healthcare Infrastructure & Facilities – Supporting pillars for pharmaceutical progress. 👩⚕️ Healthcare Workforce – Understanding the manpower driving the sector. 📊 Trade Statistics & Healthcare Spending – Key data on imports, exports, and investments. This is your chance to deepen your knowledge of Singapore’s pharmaceutical sector and gain a competitive edge. Stay informed and ahead of the curve! 🚀 #PharmaceuticalMarket #Singapore #HealthcareInfrastructure #MarketInsights #KYMSeries #CompetitiveEdge #KnowYourMarket #PharmaInnovation #BrandedDrugs #Generics #LocalManufacturing #HealthcareSpending #RASLifeScienceSolutions #MarketIntelligence #PharmaTrends #StrategySupport #PartnerIdentification #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization Follow our page for more industry updates: https://lnkd.in/de5zNWmK

This is your chance to deepen your knowledge of Singapore’s pharmaceutical sector and gain a competitive edge. Stay informed and ahead of the curve! 🚀 #PharmaceuticalMarket #Singapore #HealthcareInfrastructure #MarketInsights #KYMSeries #CompetitiveEdge #KnowYourMarket #PharmaInnovation #BrandedDrugs #Generics #LocalManufacturing #HealthcareSpending #RASLifeScienceSolutions #MarketIntelligence #PharmaTrends #StrategySupport #PartnerIdentification #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization Follow our page for more industry updates: https://lnkd.in/de5zNWmK

🚀 Transforming Healthcare in India: A New Milestone from Eli Lilly! 🌐 The healthcare and pharmaceutical industry in India is on the brink of another transformative chapter as Eli Lilly, a renowned US-based pharmaceutical company, prepares to launch its popular weight-loss drug in India next year. This strategic move highlights the increasing need for innovative treatments targeting obesity, a rising health concern globally and particularly in India. I found this development truly exciting. It showcases how advancements in medicine are shaping the future of healthcare, not just globally but also in emerging markets like India. This launch is more than just the introduction of a new drug—it represents: ✅ Innovative Approaches: Tackling lifestyle diseases like obesity with cutting-edge research and development. ✅ Market Expansion: Global pharmaceutical companies are increasingly recognizing India’s potential as a key player in healthcare innovation. ✅ Patient-Centric Solutions: Addressing accessibility and affordability to improve the quality of life for millions. 📌 Read the full story to know more about this development: https://lnkd.in/dZwAf-_x 💡 Let’s connect and discuss the impact of such innovations on the Indian healthcare system. #PharmaInnovation #HealthcareInIndia #FutureOfHealthcare #PharmaceuticalIndustry #WeightLossSolutions #HealthcareManagement #IndianPharma

Last week, the Foundation’s CEO, Jayasree Iyer, was a guest on CNBC Africa where she spoke about our latest report which examines how pharmaceutical companies are measuring and reporting #PatientReach and sets out practical recommendations that can help accelerate current efforts. Speaking to Tabitha Muthoni, Jayasree emphasised that #pharma companies should be considering the needs of patients and the burden of disease in different communities to determine the real number of patients in need of access to treatments. "If they know the need and they serve communities based on that then we will actually be bridging the gaps in #HealthEquity a lot better." Watch the guest appearance ➡ https://lnkd.in/eqftaChh #PatientCentricity #MeasuringImpact #AccesstoMedicine #EquitableAccess #AccesstoHealthcare #GlobalHealth

🚀The UAE's Pharmaceutical Industry is Thriving!   The UAE is rapidly emerging as a key player in the MENA region's pharmaceutical sector, powered by strategic investments, advanced healthcare infrastructure, and innovation. 📊 Key Highlights: - Market Growth: Valued at $4.39B in 2023, projected to reach $6.88B by 2029, with a CAGR of 7.6%. - Manufacturing Excellence: 23 centers producing 2,500+ medicines, positioning the UAE as a regional pharma hub. 🎯 Government Initiatives: - Regulatory Reforms: Simplifying approvals for global compliance. - Healthcare Investments: Expanding infrastructure and research capabilities. 🌐 Opportunities on the Horizon: - Generics on the Rise: Growing demand for affordable medications. - Strategic Location: Access to emerging MENA markets. 💡 Future Vision: With a strong focus on genomics and multi-omics, FRX is poised to collaborate with UAE pharma leaders to integrate data platforms for precision medicine, unlocking targeted therapies and shaping the future of healthcare. Let's Talk! Link: https://lnkd.in/dtbGC9XV https://lnkd.in/dcK8-3We #Pharma #LifeSciences #Innovation #HealthcareLeadership #PrecisionMedicine #FRX

🌍 Who shapes the world’s essential medicines list? The #WHO recently announced a review of the procedures for selecting essential medicines, presenting an opportunity to reflect on the evolution of the WHO Model Lists of Essential Medicines (EML) and the stakeholders influencing its priorities.   Latest publication on The Lancet by the department's PhD candidate Kristina Jenei and co-authors Camille Glaus and Prof. Kerstin Noëlle Vokinger analyse applicants for the WHO essential medicines list and discuss solutions to improve access.   📊 Key Findings: ◾ Almost 98.1% of medicines proposed to the WHO EML between 2003 and 2023 came from applicants in high-income countries. ◾ 30% of these applications were submitted by universities and research institutions, followed by NGOs, the UN system, professional associations, and the pharmaceutical industry. ◾ While over half of the Expert Committee members were from low- and middle-income countries, a central question remains: for whom is the EML intended?   🔗 Read this analysis in full 👉  https://bit.ly/3XXAVsv #EssentialMedicines #AccessToMedicine

Italy's pharmaceutical sector is one of the largest in Europe, with a total industry value of over €34 billion. Italy is also home to over 700 #biotech companies, with 75% focusing on healthcare-related research. The Italian biotech sector is particularly strong in areas such as #oncology, #rare #diseases, and #immunotherapy, providing excellent collaboration opportunities for foreign companies seeking to leverage Italy’s expertise in these fields. Italy’s strategic location within Europe and its well-established network of life sciences clusters make it an ideal entry point for #Asian biopharma companies looking to expand in the EU. However, entering the Italian market requires a strong understanding of local regulations, as well as partnerships with key stakeholders. At Zeta Health Solutions, we offer market entry support tailored to biopharma companies, helping you navigate requirements, identify key partners, and establish a strong presence in Italy and beyond. DM us to learn more about how we can support your expansion into Italy. What opportunities do you see in the Italian pharma industry? Let’s chat in the comments! #Asia #AsiaPacific #Biotech #Pharma #Foodsupplements #Europe #PharmaItaly #MarketEntry #BiotechGrowth #PharmaEurope #India #China #Philippines #USA #Canada #Thailand #Australia #Japan

Pharma companies invest millions in innovation each year. This graphic from Nicolas Schmitz clearly showcases the top pharmaceutical pipelines for 2024. However, the pressing question remains: how much of this innovation will extend beyond the US, EU and some selected Asian markets? Low- and middle-income countries around the world are unlikely to see many of these products become accessible. Why is this?  Over the years, I have focused on compassionate use and expanded access programs, helping small- to mid-sized companies strategize pathways to provide treatments to patients with life-threatening conditions. These regulatory frameworks allow patients to access drugs prior to formal approval when no other options are available. Even within these frameworks, disparities in access are significant—and the blame doesn’t solely rest with pharmaceutical companies strategies. A multitude of factors come into play. Together with Mimi Choon-Quinones Partners For Patients NGO WEP Clinical and other esteemed panelists, we will explore these disparities and discuss actionable steps to improve access to innovative medicines in underserved regions at the HEAL event in Davos next week. You can find more about this event here: https://lnkd.in/du-XMKUF Let's work towards a future where life-saving treatments are accessible to all, no matter where they live. #withEveryPatient #compassionateuse ---------------------------- Image Credits: Nicolas Schmitz